carboplan solution for infusion 150mg/15ml
vianex sa aonyme commercial-industrial-, tourist & maritime societe anonyme vianex sa tatoiou street, 18th km athens-lamia national road, nea erythrea, 146 71 , greece - carboplatin - solution for infusion - carboplatin 10 mg/ml - antineoplastic agents
panadol advance 500mg tablet, film coated tablets
haleon hellas single member societe anonyme, under the distinctive title of haleon hellas, 274, kifissias ave, 15232 chalandri, athens, greece - paracetamol - film-coated tablet - paracetamol 500 mg - analgesics
panadol extra advance 500mg /65mg tablets
haleon hellas single member societe anonyme, under the distinctive title of haleon hellas, 274, kifissias ave, 15232 chalandri, athens, greece - paracetamol, caffeine - tablet - paracetamol 500 mg caffeine 65 mg - analgesics
azithromycin-asteria tablets film-coated
one pharma industrial pharmaceutical company societe anonyme - azithromycin (azithromycin dihydrate) - tablets film-coated - 250mg
azithromycin-asteria tablets film-coated
one pharma industrial pharmaceutical company societe anonyme - azithromycin (azithromycin dihydrate) - tablets film-coated - 500mg
clopidogrel-asteria tablets film-coated
one pharma industrial pharmaceutical company societe anonyme - clopidogrel (clopidogrel bisulfate) - tablets film-coated - 75mg
gemnil 1000mg powder for solution for infusion
vianex sa aonyme commercial-industrial-, tourist & maritime societe anonyme vianex sa tatoiou street, 18th km athens-lamia national road, nea erythrea, 146 71 , greece - gemcitabine - powder for solution for infusion - gemcitabine 1000 mg - antineoplastic agents
sevenfact- coagulation factor viia recombinant human kit
laboratoire français du fractionnement et des biotechnologies société anonyme (lfb s.a.) - coagulation factor viia recombinant human (unii: ac71r787ov) (coagulation factor viia recombinant human - unii:ac71r787ov) - sevenfact [coagulation factor viia (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia a or b with inhibitors. limitation of use: sevenfact is not indicated for the treatment of patients with congenital factor vii deficiency. sevenfact is contraindicated in - known allergy to rabbits or rabbit proteins. exposure to sevenfact in these patients can result in severe hypersensitivity reaction. - patients with severe hypersensitivity reaction to sevenfact or any of its components. exposure to sevenfact in these patients can result in severe hypersensitivity reaction. risk summary there are no adequate and well-controlled studies using sevenfact in pregnant women to determine whether there is a drug-associated risk. animal studies evaluating the embryo-fetal teratogenic potential of sevenfact have not been conducted. it is unknown whether sevenfact can cause fetal harm when administered to a pregnant
oxaviatin 5 mg/ml concentrate for solution for infusion
vianex sa aonyme commercial-industrial-, tourist & maritime societe anonyme vianex sa tatoiou street, 18th km athens-lamia national road, nea erythrea, 146 71 , greece - concentrate for solution for infusion - oxaliplatin 5 mg/ml - antineoplastic agents
azithromycin-asteria tablets film-coated
one pharma industrial pharmaceutical company societe anonyme - azithromycin (azithromycin dihydrate) - tablets film-coated - 250mg